Featured Research

from universities, journals, and other organizations

Gefitinib may have chemopreventive benefits in pancreatic cancer

Date:
November 8, 2010
Source:
American Association for Cancer Research
Summary:
Gefitinib may be a promising chemoprevention agent for pancreatic cancer, according to new study.

Gefitinib may be a promising chemoprevention agent for pancreatic cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Related Articles


The study is published in the November issue, and was discussed during a press conference at the Ninth Annual Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.

Pancreatic cancer has a dismal prognosis because it is often asymptomatic and not detected until it is in late stages. Strategies to combat pancreatic cancer have focused on earlier and earlier treatments, and this is the first time that a chemoprevention strategy has been tried.

Chinthalapally V. Rao, Ph.D., director of the Center for Chemoprevention and Cancer Drug Development at the University of Oklahoma Cancer Institute, tested the strategy in mice.

The mice were bred to be at high risk for pancreatic cancer and then fed gefitinib in escalating doses of 0, 100 and 200 ppm for a period of 35 weeks, at which time the tumor incidence was analyzed.

Compared to the group that received no gefitinib, the mid-dose group experienced 77 percent fewer pancreatic tumors and the high-dose group had 100 percent fewer tumors.

In the 100 ppm group, 67.6 percent of the mice were free of pancreatic intraepithelial neoplasms, a known pre-cursor to pancreatic cancer, compared with 77.3 percent in the 200 ppm group.

"These findings are dramatic enough that human trials should begin soon," said Rao. "The clear message is that the earlier we start, the better the outcome is, and we can already measure neoplasm levels in humans so there is a potential here for clinical benefit."


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Mohammed, N. B. Janakiram, Q. Li, V. Madka, M. Ely, S. Lightfoot, H. Crawford, V. E. Steele, C. V. Rao. The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. Cancer Prevention Research, 2010; 3 (11): 1417 DOI: 10.1158/1940-6207.CAPR-10-0038

Cite This Page:

American Association for Cancer Research. "Gefitinib may have chemopreventive benefits in pancreatic cancer." ScienceDaily. ScienceDaily, 8 November 2010. <www.sciencedaily.com/releases/2010/11/101108140408.htm>.
American Association for Cancer Research. (2010, November 8). Gefitinib may have chemopreventive benefits in pancreatic cancer. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2010/11/101108140408.htm
American Association for Cancer Research. "Gefitinib may have chemopreventive benefits in pancreatic cancer." ScienceDaily. www.sciencedaily.com/releases/2010/11/101108140408.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins